ABT-333 — Competitive Intelligence Brief

ABT-333 (ABT-333) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside NS5B polymerase inhibitor. Area: Virology / Hepatology.

phase 3 Non-nucleoside NS5B polymerase inhibitor HCV NS5B RNA-dependent RNA polymerase Virology / Hepatology Small molecule

Target snapshot

ABT-333 (ABT-333) — AbbVie (prior sponsor, Abbott). ABT-333 is a non-nucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABT-333 TARGET	ABT-333	AbbVie (prior sponsor, Abbott)	phase 3	Non-nucleoside NS5B polymerase inhibitor	HCV NS5B RNA-dependent RNA polymerase
Combined therapy LDV and SOF	Combined therapy LDV and SOF	Yassin Abdelghaffar Charity Center for Liver Disease and Research	marketed	Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor)	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Simeprevir + Sofosbuvir	Simeprevir + Sofosbuvir	Federal University of São Paulo	marketed	Antiviral combination (protease inhibitor + nucleotide polymerase inhibitor)	HCV NS3/4A protease and HCV NS5B RNA-dependent RNA polymerase
Sofosbuvir-Ribavirin	Sofosbuvir-Ribavirin	Ain Shams University	marketed	Nucleotide polymerase inhibitor + nucleoside analog antiviral	HCV NS5B RNA-dependent RNA polymerase; ribavirin has multiple targets
Ledipasvir and sofosbuvir	Ledipasvir and sofosbuvir	National Taiwan University Hospital	marketed	Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor)	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Epclusa (SOF/VEL)	Epclusa (SOF/VEL)	University of California, San Francisco	marketed	Direct-acting antiviral combination (nucleotide + non-nucleoside polymerase inhibitor)	HCV NS5B RNA-dependent RNA polymerase
Sofosbuvir Oral Product	Sofosbuvir Oral Product	MTI University	marketed	Nucleotide analog NS5B polymerase inhibitor	HCV NS5B RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside NS5B polymerase inhibitor class)

1. AbbVie (prior sponsor, Abbott) · 1 drug in this class